Context Therapeutics (CNTX) Liabilities and Shareholders Equity (2020 - 2026)

Context Therapeutics has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $58.9 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $58.9 million, down 36.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $293.7 million (down 22.73% YoY), and the FY2025 annual result was $68.5 million, down 30.2% from the prior year.
• Liabilities and Shareholders Equity came in at $58.9 million for Q1 2026 at Context Therapeutics, down from $68.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $102.7 million in Q2 2024 to a low of $11.1 million in Q1 2024.
• The 5-year median for Liabilities and Shareholders Equity is $47.0 million (2022), against an average of $56.2 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 1762.65% in 2022 and slumped 65.43% in 2024, its largest moves.
• Context Therapeutics' Liabilities and Shareholders Equity stood at $38.0 million in 2022, then tumbled by 57.69% to $16.1 million in 2023, then surged by 510.9% to $98.1 million in 2024, then plunged by 30.2% to $68.5 million in 2025, then decreased by 14.07% to $58.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $58.9 million (Q1 2026), $68.5 million (Q4 2025), and $79.2 million (Q3 2025), per Business Quant data.